Who we are
Our vision becomes reality:
We want to ensure that our patients have a future worth living. Worldwide. Every day.
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases. We aim to create a future worth living for chronically and critically ill patients – worldwide and every day. We want to go a step further towards our vision by addressing the renal care continuum and with the help of critical care solutions and complementary assets.
Thereby, we rely on decades of experience in dialysis, our innovative research and our value-based care approach. We care for more than 346,500 dialysis patients. Their well-being always comes first. Our top priority is to offer them the best possible care.

346,553
patients

75%
of our patients
would highly recommend
our services to a friend

88%
of patients were treated
with in-center dialysis

12%
of patients were treated
with home dialysis

We are the clear
market leader
in the production
of hemodialysis machines

Products
and treatments
in around
150
countries

4,092
dialysis centers in
around 50 countries

44
PRODUCTION
SITES
Revenue
Despite a challenging year, we achieved our revenue target for 2020
NORTH AMERICA
EUROPE, MIDDLE EAST AND AFRICA
ASIA-PACIFIC
LATIN AMERICA
HEALTH CARE SERVICES
HEALTH CARE PRODUCTS
Operating
Income
Robust earnings growth in fiscal year 2020 despite COVID-19 pandemic
1Constant currency
22020 excluding an impairment of goodwill and trade names in the Latin America Segment; 2019 adjusted for transaction costs related to the acquisition of NxStage, Cost Optimization Costs and the (Gain) loss related to divestitures of Care Coordination activities
Net
Income
With a strong net income performance, we overachieved our financial target for 2020
1Constant currency
2Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
32020 excluding an impairment of goodwill and trade names in the Latin America Segment; 2019 adjusted for transaction costs related to the acquisition of NxStage, Cost Optimization Costs and the (Gain) loss related to divestitures of Care Coordination activities
Dividend
Based on the strong results for 2020, we plan to propose the 24th consecutive dividend increase
1Planned proposal to be approved by the Annual General Meeting on May 20, 2021
EMPLOYEES
Thanks to their tireless efforts throughout 2020, our employees have become true heroes
1Full-time equivalents
2Including Mexico